French IVD (in vitro diagnostic) rules upset EU
This article was originally published in Clinica
The EU is likely to lock horns again with France over its registration requirements for in vitro diagnostics. France's transposition of the EU's IVD Directive introduces registration requirements that go beyond those in the rest of Europe (see p 6). But the recent outcome of a European Court of Justice case between France and the European Commission over a similar issue is likely to give the French decision some credence.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.